Transcriptome profiling of wildtype mouse with metformin treatment. Mus musculus breed:C57BL/6

Metformin, one of the first-line medication for the treatment of type 2 diabetes and gestational diabetes, has recently be suggested for targeting cardiovascular disease, cancer and aging. Therefore, current understanding of the mechanism of this drug is incompletely understood, and the function of multiple tissues, other than liver metabolism alone, may be influenced. Here, we provide a comprehensive mouse transcriptome map with metformin treatment across several tissues including aorta, eyeball, brain, adipose tissue, heart, kidney, liver, skeletal muscle, stomach and testis. The wildtype healthy mice treated with metformin were compared with blank controls. The transcriptome changes with/without metformin treatment were probed by using high-throughput RNA-seq techniques. This dataset could serve as a baseline resource for investigating the potential beneficial or adverse effects of metformin across different tissues.